Millions of Part D patients who rely on price-controlled drugs will see their out-of-pocket medication costs increase.

A provision about insulin in the Inflation Reduction Act is conflated with a 2022 executive order by former President Joe Biden on lowering prescription drug costs in posts online that suggest President Donald Trump has canceled the $35 insulin co-pay cap for certain Medicare programs.

The Trump administration’s Centers for Medicare & Medicaid Services (CMS) has signaled that it will be revamping the process of negotiating prices for certain Medicare Part D drugs with input f | The agency said it is "considering opportunities to bring greater transparency" and will consider stakeholder feedback on the program.

Medicare is big business, recently providing healthcare coverage to 68 million people. It changes a little or a lot every year, and millions have strong opinions about it, too: Before the 2024 election,

The Inflation Reduction Act of 2022 has triggered a raft of changes to Medicare Part D plans and Medicare Advantage plans that affect prescription drug coverage in 2025. Here’s what to know.

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.

The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.

The talks around drugs including Novo Nordisk’s Wegovy, GSK’s Trelegy Ellipta, and Pfizer’s Xtandi will set Medicare prices that go into effect in 2027.

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.

Despite online claims, President Donald Trump’s executive orders did not include removing Medicare’s $35 monthly out-of-pocket price cap, which is set by law.

Trump has reversed some of President Biden’s initiatives, including $2 monthly out-of-pocket cap on some generics and experimental pricing models for gene therapies. But so far the healthcare elements of the Inflation Reduction Act remain unchanged.

Biden-era policies rescinded by Donald Trump could signal a significant shake-up in Medicare and Medicaid drug price reforms.